Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
HUTCHMED (China) Ltd (HCM)
Price£2.12Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $548.5M | $630.2M | $838.0M | $426.4M | $356.1M | $228.0M | $204.9M | $214.1M | $241.2M | $216.1M | $178.2M | $87.3M |
| Gross profit | $212.2M | $281.3M | $453.6M | $115.3M | — | — | — | — | $71.4M | $66.9M | $73.3M | $33.9M |
| Gross margin | 38.68% | 44.64% | 54.12% | 27.04% | — | — | — | — | 29.62% | 30.98% | 41.16% | 38.76% |
| Research & development | $148.3M | $212.1M | $302.0M | $386.9M | $299.1M | $174.8M | $138.2M | $114.2M | $75.5M | $66.9M | $47.4M | $29.9M |
| Operating expenses | $587.7M | $673.9M | $819.6M | $834.1M | $684.4M | $424.6M | $351.3M | $306.8M | $294.6M | $262.8M | $188.0M | $105.6M |
| Operating income | −$39.2M | −$43.7M | $18.4M | −$407.7M | −$328.3M | −$196.7M | −$146.4M | −$92.6M | −$53.4M | −$46.7M | −$9.8M | −$18.3M |
| Operating margin | −7.14% | −6.94% | 2.19% | −95.61% | −92.19% | −86.27% | −71.45% | −43.27% | −22.15% | −21.61% | −5.48% | −20.91% |
| EBITDA | −$25.9M | −$31.4M | $26.6M | −$399.0M | −$321.1M | −$190.6M | −$141.4M | −$89.1M | −$50.8M | −$44.4M | −$7.8M | −$17.0M |
| EBITDA margin | −4.71% | −4.98% | 3.17% | −93.58% | −90.17% | −83.61% | −69.03% | −41.59% | −21.08% | −20.53% | −4.35% | −19.46% |
| Net income | $456.9M | $37.7M | $100.8M | −$360.8M | −$194.6M | −$125.7M | −$106.0M | −$74.8M | −$26.7M | $11.7M | $8.0M | −$7.3M |
| Net profit margin | 83.30% | 5.99% | 12.03% | −84.62% | −54.66% | −55.15% | −51.75% | −34.94% | −11.08% | 5.41% | 4.49% | −8.37% |
| Basic EPSper basic share | $0.53 | $0.04 | $0.12 | -$0.43 | -$0.25 | -$0.18 | -$0.16 | -$0.11 | -$0.04 | $0.02 | -$0.06 | -$0.06 |
| Diluted EPSper diluted share | $0.52 | $0.04 | $0.12 | -$0.43 | -$0.25 | -$0.18 | -$0.16 | -$0.11 | -$0.04 | $0.02 | -$0.06 | -$0.06 |
Owners
Reported ownership
Insider buys & sells
Community posts
AstraZeneca files US application for lung-cancer combination developed with HUTCHMED
HUTCHMED ($HCM) said AstraZeneca ($AZN) submitted a US new drug application for savolitinib, marketed as ORPATHYS in other jurisdictions, combined with TAGRISSO. The proposed use is MET-driven, EGFR-mutated advanced non-small-cell lung canc ...
